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Abstract
Background: Glaucoma involves progressive optic nerve fibre loss, subsequently leading to irreversible and
disabling visual field defects. In Europe, the prevalence of glaucoma is approximately 2.2 % of all people aged over
40 years; this equates to 12 million people. Glaucoma patients require regular lifelong follow-up, contributing to a
large financial and resource burden for the National Health Service (NHS) in the UK. This study aims to determine
whether providing newly diagnosed glaucoma patients with a personalised client-held eye health summary
(‘glaucoma personal record’), improves patients’ knowledge of their glaucoma condition. A potential long-term
benefit could be improved self-management and henceforth a slower rate of deterioration.
Methods/Design: HOPE Glaucoma is a 3-year, prospective, parallel-group, pragmatic, single-centred, randomised
controlled trial. An anticipated 122 adults, newly diagnosed with glaucoma (including ocular hypertension,
suspected glaucoma and/or chronic open-angle glaucoma) will be recruited from a nurse-led ophthalmology
outpatient clinic at a medium-sized NHS Trust. Participants will be randomly allocated to receive standard clinical
care (control arm) or standard care plus a glaucoma personal record, detailing the current state of their condition
(interventional arm). Participant assessments are designed to test whether provision of a glaucoma personal record
1) improves patient knowledge of glaucoma and 2) contributes to improvements in clinical outcomes, i.e. delay of
visual field loss. The primary outcome measure is better client knowledge of glaucoma at the 9–12 month follow-up
visit. Secondary outcome measures include the rate of visual field loss and patient-reported outcome measures on
visual function (National Eye Institute VFQ – 25) measured at baseline, 9–12 months, 24 months and 36 months.
Estimating a 20 % drop-out rate, the study will have 90 % power to detect a mean two-point difference in glaucoma
knowledge score between groups at 5 % significance - based on two-sided Mann–Whitney U test.
Discussion: If a glaucoma personal record is found to significantly improve glaucoma patients’ knowledge of their
condition, this intervention could potentially provide a low-cost, straightforward tool to educate and engage glaucoma
patients. Subsequently, this could have the potential to increase patient self-management and therefore allow
glaucoma patients to prolong their sight functionality for longer.
Trial registration: ISRCTN41306818, registered on 22 August 2013.
Keywords: Glaucoma, Ocular hypertension, Chronic open-angle glaucoma, Ophthalmology, Patient education,
Knowledge, ‘Glaucoma personal record’, Client-held eye summary, Individual record of care, Randomised trial
* Correspondence: Marina.Forbes@ncuh.nhs.uk
1Clinical Nurse Specialist Ophthalmology, North Cumbria University Hospitals
NHS Trust, Cumberland Infirmary, Ophthalmology Department, Newtown
Road, Carlisle CA2 7HY, UK
Full list of author information is available at the end of the article
TRIALS
© 2015 Forbes et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Forbes et al. Trials  (2015) 16:337 
DOI 10.1186/s13063-015-0863-2
Background
Glaucoma encapsulates a disparate group of eye diseases
that are multi-factorial and individual to each patient.
The common factor is progressive optic nerve fibre loss,
which leads to irreversible and disabling visual field de-
fects if it is not diagnosed and treated early. It is esti-
mated that in Europe approximately 12 million people
are affected by glaucoma, equating to 2.2 % of the popu-
lation aged over 40 years [1]. These individuals require
lifelong review to monitor their condition and response
to topical ocular antihypertensive eye drops and/or other
treatments. As the population ages, glaucoma will con-
tinue to present a significant burden for our current
healthcare resources [2]. Improved knowledge and un-
derstanding has the potential to enhance compliance
and any tool which increases patients’ understanding of
their glaucoma should be beneficial to all stakeholders.
Beneficiaries of this research are presented in Table 1.
There are various client-held care records utilised
throughout the UK healthcare services [3–5], yet there is
a paucity of such records specifically designed for those
with glaucoma. Previous research has recognised that
clients who receive emotional support and information
at the initial diagnosis of glaucoma benefit by displaying
good compliance and co-operation with their care [6].
Individualised care of glaucoma patients, taking into ac-
count healthcare needs and patient beliefs about illness
and medicines, has also been shown to improve adher-
ence to ocular hypotensive therapy and have the poten-
tial to delay progression of the condition [7].
There is currently no available evidence of previous
efforts to produce a client-held ‘glaucoma personal rec-
ord’ for secondary care ophthalmic units and the au-
thors are not aware of any research assessing whether
client-held glaucoma personal records produce better
health outcomes in glaucoma [8]. Clinical teams may
provide numerous resources to clients, depending on
the individuals’ specific needs, yet there is potential to
produce a standardised summary that can be tailored to
record each individual’s current appearance of their
glaucoma status. This summary should add value to cli-
ent care as it would be held by each individual and per-
sonalised to reflect their condition. One would expect
that providing glaucoma clients with their own personal
‘glaucoma personal record’ or client-held eye summary,
at diagnosis, may potentially help to engage them more
effectively with their diagnosis and increase their
understanding.
National Institute of Clinical Excellence (NICE) guide-
lines on the diagnosis and management of chronic open-
angle glaucoma and ocular hypertension recommend
that research is required to assess “what is the clinical
effectiveness and cost effectiveness of providing people
with ocular hypertension (OHT), suspected glaucoma
(SG) and/or chronic open-angle glaucoma (COAG) with
a ‘glaucoma personal record’ compared with standard
treatment?” [8]. This study aims to fulfil this require-
ment by assessing the clinical effectiveness of providing
patients with OHT, SG and/or COAG (henceforth col-
lectively referred to as glaucoma) with an in-house de-
veloped ‘glaucoma personal record’, when compared with
current standard best practice.
Clinical effectiveness will primarily be measured by
assessing patient knowledge concerning his/her own
condition at 9–12 months, to coincide with a regular
follow-up visit in clinic. Furthermore, client perception
of how their glaucoma affects daily living and ophthal-
mological clinical parameters will be measured annually
for 3 years. The ultimate aim is to instigate methods of
enhancing self-management through increased glaucoma
awareness and potentially achieving deceleration of glau-
coma progression in patients.
Table 1 Beneficiaries of increased client understanding of their glaucoma
Beneficiaries Reasons
Patients/clients Receive appropriate knowledge, support and motivation to manage their condition to remain sighted
for their lifetime.
Family and caregivers Glaucoma can be hereditary. Significant life-changing effects to family and/or caregivers if visual loss is
not prevented. If relative remains sighted for their lifetime, burden of care is reduced.
Medical and nursing staff in acute care Clients carry an individualised summary of the current state of their glaucoma thus increasing
communication and continuity of care.
Ophthalmic department and organisation
(the Acute Trust)
Increased capacity to care for engaged glaucoma clients, resulting from good resource use and
high-quality service.
General practitioners and community
optometrists (primary care)
Glaucoma clients successfully self-manage their care, and can share their eye summary and health
state with primary care healthcare professionals.
Local healthcare economy Clients diagnosed with a long-term sight-threatening condition are managed within current resources,
and the burden of visual disability within the community is curbed.
Clinical nurse glaucoma specialist Job satisfaction. Professional kudos. Sense of value to all those above, but especially clients. Enjoy
sharing knowledge and skills and supporting client group.
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Methods
Trial design
This 3-year, prospective, single-centre, parallel-group,
randomised, controlled clinical trial will assess the effect
of graphic eye-health information provision to patients
with glaucoma or risk of glaucoma.
Participants and settings
Newly referred patients attending a nurse-led ophthal-
mology clinic in a medium-sized hospital in the North
of England will be assessed by the chief investigator (CI),
an ophthalmologic nurse specialist, for suitability using
the criteria detailed below:
Inclusion criteria
– Adult (age ≥18 years)
– Patients newly diagnosed with glaucoma, to include
the following three presentations:
o ocular hypertension (OHT): intraocular pressures
(IOPs) above the normal range (more than or equal
to 21 mmHg), but no signs of optic nerve fibre loss
or visual field loss
o suspected glaucoma (SG): optic nerve fibre loss or
visual field loss or both in presence of normal
intraocular pressures
o chronic open-angle glaucoma (COAG): any combin-
ation of raised intraocular pressures, optic nerve fibre
loss and/or visual field loss.
o any combination of the above OHT, SG, COAG
– Both primary (cause of outflow resistance or angle
closure is unknown) and secondary (outflow
resistance results from another disorder) glaucoma
cases can be included such as pigment dispersion
syndrome (PDS) or pseudoexfoliative glaucoma
(PEXF)
Exclusion criteria
– Under age (<18 years)
– Mental incapacity through inability to read, co-
morbidities (e.g. severe stroke, advanced dementia)
or any other contributing factor
– Inability to provide informed written consent
– Unable to speak or understand English since an
interpreter is not available throughout the course of
the study.
– Previous diagnosis of glaucoma
Other co-morbid ophthalmological conditions, such as
cataracts and age-related macular degeneration are not
listed as exclusion criteria to ensure that the study is
pragmatic.
Patients meeting the eligibility criteria will be recruited
into the trial by the CI from a ‘new glaucoma’ referral
clinic. Recruiting newly diagnosed adults, with little or
no experience of previous glaucoma services, will reduce
prior experience of secondary ophthalmic care and po-
tential educational bias.
Consent
If eligible, patients will be given verbal and written infor-
mation on the study by the CI during their consultation
to avoid sensitisation to the objectives of the study. One
key aspect of the study is to avoid priming patients
about the potential benefit of education (utilising a post-
test-only design). If patients are willing to participate,
written informed consent will be obtained by the CI at
the same consultation. There is, therefore, a limited time
frame for patients to make a decision about participa-
tion. However, the patient information sheet will stress
that there is a ‘cooling-off ’ period and that patients can
change their mind regarding participation at any given
time. If a participant is already enrolled in another study,
then he/she will be allowed to participate in this trial
provided the other study does not exclude him/her from
doing so.
Sample size
The anticipated patient sample size of 122 will be re-
cruited over a 12-month period. Power calculations for
sample size, 90 % power and 5 % significance, based on
two-sided Mann–Whitney U test for the primary out-
come measure, patient knowledge of glaucoma. A priori
power calculations, using GPower 3.1 software, result in
the following sample sizes summarized in Table 2. The
calculation also takes into account a 20 % drop-out rate
over the initial 9–12-month follow-up period before pa-
tients return for their regular glaucoma follow-up and
knowledge questionnaire visit.
Randomisation
Each participant will be assigned to the control or inter-
ventional arm by a pragmatic randomisation approach;
there will be no stratification and randomisation will
take place on a 1:1 ratio without blocking. Online free-
ware will be used to generate a random allocation se-
quence in advance of the recruitment period, seen only
by the trial administrator (who will not be involved with
data collection) [9]. Allocation concealment will be
achieved using consecutively numbered, sealed, opaque
envelopes prepared in advance of recruitment by the
trial administrator. This will ensure the investigator is
not aware of the allocation sequence in advance of
randomization. Eligible subjects will be randomised and
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- if assigned to the intervention arm - presented with
their glaucoma personal record by the CI immediately
after written informed consent has been obtained. For
overview of the study process, see Fig. 1.
Intervention description
Both groups will have exposure to current educational
resources and materials presented at diagnosis, as is
standard clinical practice. This may include an enlarged
model of the eye, ocular anatomy posters, ocular coher-
ence tomography sample scans, images of healthy and
damaged optic nerve heads, examples of normal visual
field tests and those showing glaucomatous loss, and a
glaucoma information leaflet to take away with them.
The chief investigator’s contact number will also be pro-
vided, as would be standard in her capacity as clinical
nurse specialist in ophthalmology.
Those participants allocated to the interventional arm
will, in addition to standard clinical care, be provided
with their own ‘glaucoma personal record’ (Additional
file 1), which will be personalised to document the
current state of each participants’ glaucoma diagnosis
and utilised during ophthalmologic review. Both groups
of participants will be asked to complete the National
Eye Institute Visual Functioning Questionnaire – 25
(VFQ-25) to gain an insight into patients’ perceptions
about the impact that glaucoma may have on their daily
living. The ‘glaucoma personal record’ will be adminis-
tered to those participants randomised to receive the
intervention by the CI immediately after the informed
consent process has been completed.
Intervention development
Recent work by Waterman [10] identified the need for
patients to be informed about their glaucoma, to help
them understand their condition and the implications of
poor medication adherence. The glaucoma personal rec-
ord used in the HOPE Glaucoma trial (Additional file 1)
was developed from the concept of the Spaeth-coloured
glaucoma graph for diagnosed glaucoma patients and
glaucoma suspects [11]. This graph provides both pa-
tients and clinicians with visual information concerning
current optic disc appearance. Spaeth and Paulus [11]
claimed it is user-friendly because of the traffic light sys-
tem. They also claimed that most patients understand
that green indicates ‘safe’, yellow/amber means ‘caution’,
and red means ‘danger’. They proposed that “the graph
can help in patient counselling by increasing the under-
standing regarding the disease status”. The work from
Spaeth and Paulus inspired application of a traffic light
system to visual field scoring using the Hoddap Classifi-
cation [12, 13].
Although staging systems may be of limited value in
clinical practice, the authors intended to put together an
inexpensive yet useful ‘glaucoma personal record’. The
Hoddap system has three stages, namely, early, moderate
and advanced glaucomatous loss. The rate of progres-
sion of visual field loss will be measured by regression
analysis of the mean deviation from the mean, expressed
in decibels per year. Since this glaucoma personal record
is intended to help patients understand their current
measures according to a traffic light system, best evi-
dence available has to be balanced with simplicity, in
order to be useful.
The third fundamental measure obtained at regular
glaucoma review appointments is intraocular pressure
(IOP). Elevated IOP above 21 mmHg is considered a
Table 2 Sample size calculation
Mean score control
group (± SD)
Mean score intervention
group (± SD)
Required total
sample size, n
7 (3) 8 (3) 400 (200 per group)
7 (3) 9 (3) 122 (61 per group)
7 (3) 10 (3) 58 (29 per group)
SD standard deviation
Fig. 1 HOPE trial schema
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major risk factor in glaucoma pathology. Normal IOP is
considered to be less than or equal to 20 mmHg. Apply-
ing the traffic light system here means lower IOPs lie
within the green ‘safe’ zone. IOPs between 21 and 30
mmHg - the amber zone - are observed with caution, al-
though many other factors must be taken into consider-
ation e.g. central corneal thickness, visual field loss or
suspicious optic discs. Any IOP above 30 mmHg, the
red zone, usually means antihypertensive treatment is re-
quired as risk of glaucomatous damage or vein occlusion
is considered too high to leave untreated.
The current glaucoma personal record under investi-
gation is a coloured, A5-sized (or A4 if required), book-
let of 16 pages. It was refined with advice from the
International Glaucoma Association, who provided fi-
nancial sponsorship for this study. This prototype glau-
coma personal record is open to development and
further refinement, depending on feedback and out-
comes of this study.
Objective
This study aims to assess whether patient education,
through the provision of a glaucoma personal record, re-
sults in increased knowledge of their condition and
whether this contributes to positive behavioural change
and a reduction in the rate of visual field loss. The null
hypothesis is that a patient-specific glaucoma personal
record has no effect on client knowledge of glaucoma
(OHT, SG or CAOG), quantified using a validated
researcher-conducted survey at 9–12 months post-
recruitment.
Outcome measures
Primary outcome
The primary outcome measure is client knowledge of
glaucoma, quantified using a validated researcher-
conducted survey at 6–12 months post-recruitment [8],
see Table 3. This survey and scoring system was used,
and validated by ophthalmic colleagues in 2009/2010 “to
establish the impact of educational support on clients’
knowledge of glaucoma and adherence, in preparation
for a further interventional study” [9]. It provides an or-
dinal score of participants’ knowledge. The primary out-
come measure is therefore the degree of understanding
and knowledge retention of their OHT, SG, or COAG in
the interventional group compared with the control
group. Patients requiring ocular antihypertensive treat-
ment at first presentation are eligible for inclusion in
this trial; the total knowledge score achievable is either
12 for those not prescribed antihypertensive drops, or 17
for those prescribed eye drops during the course of the
study. The survey will be administered by the CI when
participants attend a ‘glaucoma review’ outpatient clinic
between 6 and 12 months post-recruitment.
Secondary outcomes
The secondary, longer-term, outcome measure is rate of
visual field loss. In line with clinical practice, visual field
loss will be measured at least annually (more frequently
if there is a clinical indication). The relative visual loss
rates between control and intervention groups will also
be measured annually. Visual field testing will be per-
formed by standard automated perimetry (SAP) using
the Humphrey Central 24–2 programme. The Hum-
phrey perimeter provides print-outs with statistical ana-
lyses of single field-test results, including numerical
indices of reliability, and deviation from the norm of
age-matched visual field analyses. The visual field indices
used to identify progression of visual field loss will be
mean deviation (MD) from the mean. MD represents
the average difference between normal age-corrected
sensitivity values and the subjects’ measured values at all
test points. The rate of progression of visual field loss
will be measured by linear regression analysis of the MD
from the mean, expressed in decibels per year (or the
newer visual field index, which was not available at the
start of this study).
A simple measure was selected for use in this trial.
However, there are challenges to using visual field ana-
lyses to detect progression. The test is subject to vari-
ability in performance, even for the same patient.
Modern perimetry attempts to reduce sources of error
in, for example, reduced test time, continuous gaze/fix-
ation monitoring. The role of the operator is crucial in
assisting patients to perform the test as accurately as
possible [13]. All visual field testing will be undertaken
by the CI to reduce inter-assessor variability.
Trend analyses to quantify rate of visual field loss re-
quire at least five tests to detect progression. This means
relatively frequent testing in the first 2 years following
diagnosis, especially if patients initially present with loss.
The European Glaucoma Society (EGS) suggest three
tests a year in the first 2 years. As such, this secondary
outcome measure will take approximately 2–5 years to
establish. The MD score will be documented in the
‘glaucoma personal record’ for the intervention group,
and obtained from standard medical records for the con-
trol group.
The impact of visual field loss on patients’ lives will be
measured using the vision-targeted health-related quality
of life (HRQOL) measure: the National Eye Institute Vis-
ual Functioning Questionnaire – 25 (VFQ-25). This vali-
dated patient-reported outcome measure tool was
designed to measure the impact of visual deficit on
physical functioning, emotional well-being and social
functioning [14]. The VFQ-25 will be completed by par-
ticipants attending the CI’s nurse-led glaucoma review
outpatient clinic at baseline, 6–12 months, 24 month
and 36 months post-recruitment.
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The patient glaucoma record will use ‘traffic light’
graphs to make it more straightforward for patients to
see the status of their glaucoma for e.g. visual field loss
[11]. A copy of the patient glaucoma record is available
(Additional file 1).
Tertiary outcome
Participants’ demographic data will be collected and ana-
lysed to compare the distribution between control and
intervention groups in terms of: age, gender, postcode and
highest level of education achieved. The latter two are of
particular relevance as the study will assess self-education
and disease awareness [15]. The control and intervention
groups will also be stratified by disease diagnosis (OHT, SG
and COAG), although the aforementioned primary and
secondary outcome measures are based on collective data.
Other potential confounding factors that will be recorded
for each participant are related to general eye health and the
resulting management of the newly diagnosed glaucoma. It
will be recorded if patients: have never worn glasses/lenses,
wear glasses/lenses due to old age (reading and/or driving),
wear glasses since childhood or early adulthood due to con-
genital visual defect. Note will also made whether patients
are prescribed IOP-lowering eye drops or undergo a laser or
surgical intervention during the study period.
Data collection and monitoring
Participant follow-up will be 3 years. The estimated pri-
mary completion date is September 2015 and the esti-
mated study completion date is September 2017. An
overview of the study timeline and recorded outcome
measures are detailed in Table 4. Outcome data will be
collected during clinically scheduled ophthalmology out-
patient appointments with the CI and subjects will not be
asked to attend any additional clinic appointments above
those required for their clinical care. This design was used
to increase the pragmatism of the study and improve sub-
ject retention throughout the duration of the study. Out-
come data will not be collected for patients that withdraw
from the study or deviate from the study timeline.
All data will be entered into a trial-specific database by
a single administrator as they accumulate, access to
Table 3 The scoring system used to establish participants’ knowledge of glaucoma and its management. Source: [9]
Number Question Scored 0 Scored 1 Scored 2 Scored 3 Max
score
1 Can you tell me what you think glaucoma is? Don’t know/
incorrect answer
Build up of pressure,
raised/high pressure,
nerve damage, loss of
vision
Optic nerve
damage,
irreversible vision
loss, chronic
disease, slowly
progressive
(in own words)
NA 2
2 Can you tell me which part of the eye can
become damaged with glaucoma?
Don’t know/
incorrect answer
Back of the eye Retina Optic
nerve
3
3 Can you tell me what effect glaucoma has
on vision if left untreated?
Don’t know/
incorrect answer
You go blind/you
gradually go blind/
you lose vision
You get tunnel
vision
NA 2
4 Can you tell me what part of vision
glaucoma affects the most?
Don’t know/
incorrect answer
Visual field/field of vision/side
vision
NA NA 1
5 Is glaucoma hereditary/does glaucoma run
in families?
No/don’t know Yes NA NA 1
6 Do you know what investigations/tests will
be carried out regularly at future clinic
appointments to monitor changes in your eyes?
Don’t know/
incorrect answer
Either IOP measurement,
visual field test or optic
nerve examination (in own
words)
Any two of the
tests (in own
words)
All three
tests (in
own
words)
3
7 Do you know the name(s) of the drop(s) that has/
have been prescribed for you?
Don’t know/
incorrect answer
Yes (client named the drops) NA NA 1
8 Do you know what the drops do? Don’t know/
incorrect answer
Lower/reduce/control eye
pressure
NA NA 1
9 Do you know when you will need to collect your
next prescription?
Don’t know/
incorrect answer
1 month/28 days NA NA 1
10 After opening a bottle of drops do you know how
long you can use them before they reach their
expiry date?
Don’t know/
incorrect answer
1 month/28 days NA NA 1
11 Do you know how long you will have to use
drops for?
Don’t know/
incorrect answer
For life/forever NA NA 1
Maximum total score achievable: 17. IOP intraocular pressure
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which will be restricted and secure. All trial data will be
pseudoanonymised by use of unique participant trial
numbers. Access to the final data set will be limited to
the trial administrator (HF) and statistician (LJ). A data
monitoring committee will not be utilised throughout
the study, but the study sponsor will audit study conduct
and data quality as part of the sponsors’ existing annual
audit process. As the study intervention has no impact
on the clinical management of glaucoma patients, there
are minimal safety concerns for those involved with the
HOPE Glaucoma study. Data on solicited and spontan-
eously reported adverse events will not be collected.
Data analysis
Patient eligibility, recruitment and retention through the
study will be presented in a CONSORT flow diagram
displaying the number of eligible patients, patients
approached with study information, patients recruited
and randomised and patients completing study follow-
up. Reasons for loss to follow-up will also be presented,
where known. Participant baseline details and descriptive
statistical data will be tabulated to show overall recruit
demographics, and any differences in distribution (e.g.
patient age, sex, level of education) will be analysed by
applying one-way ANOVA or chi-squared test.
The primary outcome, the degree of difference in pa-
tient knowledge about their glaucoma condition will be
analysed by comparing the average scores for control pa-
tients versus the average score of patients received the
glaucoma personal record. Statistical significance will be
assessed by applying the Mann–Whitney U test. The
secondary outcome, visual field loss, will be measured
with a Humphrey Automated Visual Field Analyser in
the ophthalmology clinic and average measurements for
baseline visit and the final visit at 36 months will be
compared within each group (control and intervention
respectively) and also between the two groups. Depend-
ing on distribution of the data, determined by Shapiro-
Wilk test, the paired t test or Wilcoxon test will be
applied for paired samples to determine any significant
changes in visual field loss. For assessing differences be-
tween the control and intervention groups, either t test or
Mann–Whitney U test will be applied. Like visual field
loss, the other secondary outcome measure - patient-
related outcome measure VFQ-25 - will be presented as
average scores. Any statistical differences will be assessed
by Wilcoxon test within each group and Mann–Whitney
U test between groups.
Research governance
Approval and support for this study has been obtained
from the following bodies: the National Research Ethics
Service (reference 12-YH-0471) and the sponsor, North
Cumbria University Hospitals NHS Trust. Contact per-
son for the sponsor is the R&D director, Dr Jim George.
There is no provision made for non-negligent liability; the
CI and other research team members are covered by
standard NHS indemnity. The study is funded by a Nurse
Research Grant from the International Glaucoma Associ-
ation, based on the ethically approved study protocol (ver-
sion 1, 19 September 2012) and supporting study
documents (i.e. patient information sheet, consent form,
‘glaucoma personal record’) [16].
Publication and data-sharing policy
The study results will be presented at (inter)national sci-
entific meetings and at local seminars and conferences.
The results from the study will be written up and sub-
mitted to a peer-reviewed journal. We intend to write a
summary sheet for distribution in, e.g., ophthalmology
waiting areas. This summary sheet can also be distrib-
uted to participants upon request. All published data will
not contain information that can identify any of the sub-
jects who have participated in the study, in line with the
Data Protection Act [17]. Each participant will be given a
study number so that the data can be pseudoanonymised.
Discussion
The NICE Guideline Development Group published rec-
ommendations for research into the clinical effectiveness
of providing people with COAG with a ‘glaucoma personal
record’ when compared with standard treatment [8]. To
the authors’ knowledge, the HOPE Glaucoma study con-
stitutes the first effort towards fulfilling NICE recommen-
dations and the planned publication of study findings in
circa 2017 will provide the first data generated by a rando-
mised controlled trial on ‘glaucoma personal record’
provision. Findings will strengthen the evidence base avail-
able for glaucoma management guideline development
and may have a positive impact upon the future education
and care of glaucoma patients.
Strengths of the trial include the use of a time-matched
control, the random allocation of the ‘glaucoma personal
record’, allocation concealment to minimise selection bias,
long-term recruit follow-up (36 months) and the use of
validated questionnaires to capture outcome data. Due to
its fairly pragmatic approach, the trial is not without limi-
tations. The decision not to collect detailed data on patient
co-morbidities could omit potential confounding factors
throughout this trial. Other foreseeable study limitations
Table 4 Overview of study timeline and outcome measures
Baseline Baseline 9–12 months 24 months 36 months
Patient knowledge X
Patient perspective
(VFQ-25)
X X X X
Clinical parameters X X X X
VFQ-25 National Eye Institute Visual Functioning Questionnaire – 25
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include a limited patient demographic, due to recruitment
from a single-centre in a rural location with a limited ethnic
variety. The generalisability of trial findings may also be
limited by the selection of participants from a nurse-led
clinical nurse specialist new glaucoma referral clinic only.
Gray et al. [9] indeed found that the depth of information
provided for newly diagnosed patients varied across clinics
and between individual clinicians. Despite this limitation,
the use of one glaucoma practitioner throughout the dur-
ation of the trial offers a means of standardising the type
and quality of information and materials given to all partici-
pants at diagnosis and during follow-up review. Variability
in the nature of the information provided at diagnosis and
in the quality of outcome measure assessment will be mini-
mised, as the CI will be responsible for the provision and
adaptation of care for all participants, according to the indi-
vidual clinical need, and regardless of the arm to which they
were allocated.
One other limitation of the trial includes the risk of bias.
Due to the nature of the intervention - provision of a book-
let - it is not feasible to mask participants to which arm of
the study they will be allocated to. The CI is responsible for
determining the suitability of participants, allocating the
intervention and collecting data for the outcome measures
in this trial, which introduces other sources of potential
bias. The outcome assessor will not be masked to the inter-
ventional group, as the assessor distributed the ‘personal
glaucoma record’ and clients will return with (or refer too)
their record at follow-up; this increases the risk of detection
bias. However, the utilisation of a second outcome assessor
was deemed unworkable, and a pragmatic approach with
one assessor was adopted.
The use of a ‘glaucoma personal record’, such as the one
produced for this trial, for those diagnosed with OHT, SG
and/or COAG may provide an additional, low-cost source
of information to patients and other ophthalmic health-
care professionals which is easily produced and adminis-
tered. Glaucoma personal records may have the potential
to improve patients’ understanding of their condition, help
reduce patient uncertainty and potentially improve medi-
cation adherence [18].
Trial status
Recruitment to the HOPE Glaucoma study began in June
2013. Recruitment is ongoing, with 85 % of the sample
size achieved. The study is anticipated to reach the re-
cruitment target of 122 participants in September 2014.
Additional file
Additional file 1: Glaucoma personal record. This is the study
intervention;a booklet that can be personalised to contain participant’s clinical
information relevant to their glaucoma. Only participants randomised to the
interventional arm are provided with this booklet. (PDF 320 kb)
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